First Time Loading...
R

Rhone Ma Holdings Bhd
KLSE:RHONEMA

Watchlist Manager
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Watchlist
Price: 0.665 MYR 0.76%
Updated: Jun 11, 2024
Section:
 

Relative Value

The Relative Value of one RHONEMA stock under the Base Case scenario is 0.983 MYR. Compared to the current market price of 0.665 MYR, Rhone Ma Holdings Bhd is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RHONEMA Relative Value
Base Case
0.983 MYR
Undervaluation 32%
Relative Value
Price
R
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
95
vs Industry
78
Median 3Y
0.8
Median 5Y
0.8
Industry
2.3
Forward
0.7
More Details
12.1
P/E
P/E
Price to Earnings
12.1
vs History
85
vs Industry
34
Median 3Y
12.6
Median 5Y
13
Industry
22.1
Forward
10.5
More Details
5.4
P/OCF
P/OCF
Price to OCF
5.4
vs History
71
vs Industry
44
Median 3Y
6.2
Median 5Y
11.6
Industry
16.5
More Details
6.2
P/FCFE
P/FCFE
Price to FCFE
6.2
vs History
30
vs Industry
32
Median 3Y
-16
Median 5Y
-10.9
Industry
22.8
More Details
0.9
P/B
P/B
Price to Book Value
0.9
vs History
95
vs Industry
64
Median 3Y
1
Median 5Y
1
Industry
2
More Details
0.6
EV/S
EV/S
Enterprise Value to Sales
0.6
vs History
95
vs Industry
81
Median 3Y
0.8
Median 5Y
0.9
Industry
2.5
Forward
0.6
More Details
2.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.4
vs History
95
vs Industry
67
Median 3Y
2.9
Median 5Y
3.1
Industry
5
More Details
5.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.3
vs History
95
vs Industry
45
Median 3Y
6.6
Median 5Y
7.3
Industry
13.3
Forward
5.4
More Details
6.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6.3
vs History
95
vs Industry
42
Median 3Y
7.9
Median 5Y
8.8
Industry
16.5
Forward
6.4
More Details
4.8
EV/OCF
EV/OCF
Enterprise Value to OCF
4.8
vs History
71
vs Industry
46
Median 3Y
6.6
Median 5Y
12
Industry
15.2
More Details
5.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
5.3
vs History
44
vs Industry
34
Median 3Y
7.5
Median 5Y
-6.7
Industry
18
More Details
0.8
EV/IC
EV/IC
Enterprise Value to IC
0.8
vs History
95
vs Industry
66
Median 3Y
0.9
Median 5Y
0.9
Industry
1.8
More Details

Multiples Across Competitors

RHONEMA Competitors Multiples
Rhone Ma Holdings Bhd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
MY
Rhone Ma Holdings Bhd
KLSE:RHONEMA
147.1m MYR 0.7 12.1 5.3 6.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
822.1B USD 22.9 133.9 65.4 74.4
DK
Novo Nordisk A/S
CSE:NOVO B
4.4T DKK 18 49.4 36.8 40.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
354.1B USD 4.1 9.2 11.3 14.8
US
Merck & Co Inc
NYSE:MRK
333B USD 5.4 144.4 35.9 58.7
UK
AstraZeneca PLC
LSE:AZN
195.3B GBP 5.2 39.3 175.3 279.6
CH
Roche Holding AG
SIX:ROG
191.1B CHF 3.3 16.6 9.4 11.2
CH
Novartis AG
SIX:NOVN
184.5B CHF 3.5 11.7 8.9 13
US
Pfizer Inc
NYSE:PFE
159.1B USD 2.9 -514.8 12.6 20.3
P/E Multiple
Earnings Growth
MY
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Average P/E: 52.1
12.1
23%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
133.9
364%
DK
Novo Nordisk A/S
CSE:NOVO B
49.4
82%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.2
-21%
US
Merck & Co Inc
NYSE:MRK
144.4
7 598%
UK
AstraZeneca PLC
LSE:AZN
39.3
175%
CH
Roche Holding AG
SIX:ROG
16.6
28%
CH
Novartis AG
SIX:NOVN
11.7
17%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -514.8
684%

See Also

Summary
RHONEMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
RHONEMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RHONEMA stock valuation using valuation multiples.
Wall Street Estimates
RHONEMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RHONEMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 146,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.